The Midlands Therapeutic Review and Advisory Committee (MTRAC) has reviewed the evidence for the three Cox-II NSAIDs.
They have issued review on:
The reviews covered 25 randomised controlled studies involving celecoxib, 13 involving etoricoxib and 8 involving lumiracoxib. All three reviews found that evidence of efficacy for these drugs was strong but concerns about cardiovascular safety gives this class of drugs a low place in therapy.
Action: These review provide a useful summary and reminder of the efficacy and safety evidence for Cox-II NSAIDs.
|« Inhaled Insulin Launched||BNF for Children 2006 »|